V
Veerle A. Derleyn
Publications - 2
Citations - 495
Veerle A. Derleyn is an academic researcher. The author has contributed to research in topics: Bevacizumab & Colorectal cancer. The author has an hindex of 2, co-authored 2 publications receiving 415 citations.
Papers
More filters
Journal ArticleDOI
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H.J. Simkens,Harm van Tinteren,Anne May,Albert J. ten Tije,Geert-Jan Creemers,Olaf Loosveld,Felix E de Jongh,Frans L. G. Erdkamp,Zoran Erjavec,Adelheid M. E. van der Torren,Jolien Tol,Hans J Braun,Peter Nieboer,Jacobus J.M. van der Hoeven,Janny G. Haasjes,Rob L. H. Jansen,Jaap Wals,Annemieke Cats,Veerle A. Derleyn,Aafk E. H. Honkoop,Linda Mol,Cornelis J. A. Punt,Miriam Koopman +22 more
TL;DR: Maintenance treatment with capecitabine plus bevacizumab after six cycles of CAPOX-B in patients with metastatic colorectal cancer is effective and does not compromise quality of life.
Journal ArticleDOI
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy
Lieke H.J. Simkens,Miriam Koopman,Linda Mol,Gerrit Jan Veldhuis,Daan ten Bokkel Huinink,Erik W. Muller,Veerle A. Derleyn,Steven Teerenstra,Cornelis J. A. Punt +8 more
TL;DR: Investigation of the effect of body mass index on overall survival in ACC patients receiving systemic treatment in two large phase III studies shows that BMI is an independent prognostic factor for survival in Patients receiving chemotherapy, but not in patients receiving chemotherapy and targeted therapy.